Government health agencies and pharmaceutical manufacturers are finding ways to fight counterfeit and substandard drugs by identifying them from manufacturing, throughout the supply chain, and eventually when they reach the public after they are sold in the retail pharmacies. This whitepaper is co-authored by speaker Ravi Kalyanaraman of Bristol-Myers Squibb.
One of the major aspects of anti-counterfeiting and brand protection for pharmaceuticals is the implementation of serialization along the supply chain. Ahead of the 7th Pharma Anti-Counterfeiting & Brand Protection summit, we examined the role that serialization challenges play on counterfeiting in pharmaceuticals, as well as sessions from the upcoming event that can help to provide more insight. To learn more about these challenges, as well as specifics regarding our corresponding sessions, make sure to download the report.
Detailed is an abbreviated list of Anti-Counterfeiting executives who attended the last iteration of the event. Will you be there to see what they experienced?
How can the patient be sure the medication he/she is going to take is exactly what the doctor ordered? Every year, substandard, spurious, falsely-labeled, falsified and counterfeit drugs work their way into the market and eventually into the homes and hands of pateitns treating everything from routine illnesses to chronic conditions. If you would prefer to receive a copy instead, please email Max.Miller@iqpc.com
The 7th Annual Anti-Counterfeiting for Pharmaceuticals Summit takes a comprehensive approach to understand the latest regulations for the DSCSA to remain compliant and uphold quality throughbrand protections plans and anti-counterfeiting strategies. Get your copy of the preliminary draft agenda! Or have it sent to your inbox by emailing email@example.com
Prior to the Anti-Counterfeiting in Pharma & Brand Protection Summit in March, we sat down for an interview with Brian Files to discuss the largest challenges and implications in integrating serialization into the supply chain, what 2024 and beyond will look like, how new technologies will affect us, the major issues anticipated after the 2018 goal is met and more. Brian is a Principal Consultant at Healthcare Strategies Consulting Group and was formerly the Supply Chain Policy and Compliance Director at CVS Health.